Cyril Garrouste - Concepedia

Author

Cyril Garrouste

Centre Hospitalier Universitaire de Clermont-Ferrand ORCID

Also Known As

C Garrouste, C. Garrouste, Christophe Mariat, Cyril Garrouste, Cyrille Garrouste, D Van Raemdonck, Garrouste, C., Garrouste, Cyril, Hélène Francois, Mariat, Christophe

172

Publications

5.2K

Citations

H-Index

Concepts

All Affiliations

Centre Hospitalier Universitaire de Clermont-Ferrand Inserm Assistance Publique – Hôpitaux de Paris Sorbonne Université Université Toulouse III - Paul Sabatier

About

Cyril Garrouste is an author at Centre Hospitalier Universitaire de Clermont-Ferrand specializing in medicine, nephrology, and kidney transplant.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	21	2.1K
2	Public Health	2	2	247
3	Biostatistics	2	2	73
4	Health Sciences	1	1	16
5	Biomedical Engineering	1	1	15

Cyril Garrouste

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
Factors Associated With Chronic Hepatitis in Patients With Hepatitis E Virus Infection Who Have Received Solid Organ Transplants Nassim Kamar, Cyril Garrouste, Elizabeth B. Haagsma, Gastroenterology TransplantationHepatologyViral HepatitisChronic HepatitisSolid Organ Transplantation	2011	652
Development and Validation of a Modified Full Age Spectrum Creatinine-Based Equation to Estimate Glomerular Filtration Rate Hans Pottel, Jonas Björk, Marie Courbebaisse, Annals of Internal Medicine	2020	358
Ribavirin Therapy Inhibits Viral Replication on Patients With Chronic Hepatitis E Virus Infection Nassim Kamar, Lionel Rostaing, Florence Abravanel, Gastroenterology Viral PersistenceHepatologyViral HepatitisAntiviral Drug DevelopmentAntiviral Therapy	2010	276
An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants Sophie Caillard, Dany Anglicheau, Marie Matignon, Kidney International	2020	250
Influence of Immunosuppressive Therapy on the Natural History of Genotype 3 Hepatitis-E Virus Infection After Organ Transplantation Nassim Kamar, Florence Abravanel, Janick Sèlves, Transplantation	2010	229
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink, The Lancet	2023	224
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment Éric Rondeau, Marie Scully, Gema Ariceta, Kidney International	2020	203
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers, The Lancet GlomerulonephritisActive-controlled Clinical TrialRenal FunctionKidney FailureChronic Kidney Disease	2023	203
Pegylated Interferon‐α for Treating Chronic Hepatitis E Virus Infection after Liver Transplantation Nassim Kamar, Lionel Rostaing, Florence Abravanel, Clinical Infectious Diseases HepatologyViral HepatitisImmunologyAntiviral TherapyHepatitis	2010	196
Characteristics of Autochthonous Hepatitis E Virus Infection in Solid‐Organ Transplant Recipients in France Florence Abravanel, Nassim Kamar, Karine Sauné, The Journal of Infectious Diseases	2010	188

Page 1